首页> 外文期刊>The Journal of Urology >Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele.
【24h】

Repeated intradetrusor botulinum toxin type A in children with neurogenic bladder due to myelomeningocele.

机译:小儿脑膜脊髓膨出导致神经源性膀胱儿童反复出现A型肉毒杆菌毒素。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: We evaluated the effect of repeated intradetrusor injections of BTA in pediatric myelomeningocele not responding to medical management. MATERIALS AND METHODS: After baseline history, physical examination and urodynamic assessment BTA was injected (5 IU/kg body weight, maximum 300 IU) at 10 to 30 sites. Clinical and urodynamic assessment was performed at 3 months after each injection. Re-treatment was offered when clinical symptoms returned. RESULTS: A total of 20 patients (average age 13 years) received BTA injections. Of the patients 13 became continent. MBC increased from 215.6 +/- 58.8 cc to 338.3 +/- 98.4 cc (p < 0.01), MDP decreased from 43 +/- 13.7 cm H2O to 21.6 +/- 10.5 cm H2O (p < 0.01) and compliance increased from 5.2 +/- 2.6 ml/cm H2O to 13 +/- 6.9 ml/cm H2O (p < 0.01). At an average of 8.1 months after the first injection all 13 patients received a second injection, which led to similar improvement, ie MBC increased from 200.5 +/- 41.6 cc to 404.2 +/- 57.8 cc (p < 0.001), MDP decreased from 48.18 +/- 6.1 cm H2O to 27.8 +/- 3.7 cm H2O (p < 0.01) and compliance increased from 6.0 +/- 3.1 ml/cm H2O to 15.1 +/- 5.2 ml/cm H2O (p < 0.01). Among the responders 3 received 3 injections and 1 received 4 injections, all of whom exhibited improvement similar to that seen initially. Among our initial cohort of 20 patients 7 failed to improve initially and 6 failed to improve after a second injection. CONCLUSIONS: BTA seems to be a simple and safe way to postpone or avoid invasive procedures in two thirds of children with myelomeningocele not responding to usual medical treatment.
机译:目的:我们评估了在无反应的小儿脊髓膜脑膨出中反复注射内消旋BTA的效果。材料与方法:基线史后,在10至30个部位注射BTA(5 IU / kg体重,最大300 IU)。每次注射后3个月进行临床和尿动力学评估。当临床症状恢复时,可以进行再次治疗。结果:总共有20名患者(平均年龄13岁)接受了BTA注射。病人中有13人成为了大陆。 MBC从215.6 +/- 58.8 cc增加到338.3 +/- 98.4 cc(p <0.01),MDP从43 +/- 13.7 cm H2O减少到21.6 +/- 10.5 cm H2O(p <0.01),顺应性从5.2增加+/- 2.6 ml / cm H2O至13 +/- 6.9 ml / cm H2O(p <0.01)。在第一次注射后平均8.1个月,所有13例患者都接受了第二次注射,这导致了类似的改善,即MBC从200.5 +/- 41.6 cc增加到404.2 +/- 57.8 cc(p <0.001),MDP从48.18 +/- 6.1 cm H2O到27.8 +/- 3.7 cm H2O(p <0.01),顺应性从6.0 +/- 3.1 ml / cm H2O增加到15.1 +/- 5.2 ml / cm H2O(p <0.01)。在响应者中,有3人注射了3次注射,有1人接受了4次注射,所有这些人都表现出与最初所见相似的改善。在我们最初的20例患者中,有7例最初没有改善,而6例第二次注射后没有改善。结论:BTA似乎是推迟或避免侵入性手术的三分之二的髓鞘膜囊肿患儿对常规药物没有反应的简单安全的方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号